{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:06:46Z","timestamp":1776406006446,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/maj.0b013e31828abcfd","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T12:51:32Z","timestamp":1364302292000},"page":"284-288","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacotherapy of Obesity: Clinical Treatments and Considerations"],"prefix":"10.1016","volume":"345","author":[{"given":"Kelly Anne","family":"Holes-Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathie","family":"Hermayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0010","unstructured":"Behavioral Risk Factor Surveillance System. CDC. Available at: http:\/\/www.cdc.gov\/obesity\/data\/adult.html"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(11)60813-1","article-title":"The global obesity pandemic: shaped by global drivers and local environments","volume":"378","author":"Swinburn","year":"2011","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0020","series-title":"Safety of Obesity Drugs","author":"Gupta","year":"2012"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0025","series-title":"Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report","author":"National Heart, Lung, and Blood Institute","year":"2010"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0030","first-page":"347","article-title":"A controlled trial of naltrexone in obese humans","volume":"9","author":"Malcolm","year":"1985","journal-title":"Int J Obes"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0045","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0050","series-title":"Belviq Package Insert Information","author":"Arena Pharmaceuticals","year":"2012"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0055","series-title":"Qsymia Package Insert Information","author":"Vivus Inc","year":"2012"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0060","series-title":"FDA Approves Belviq to Treat Some Overweight or Obese Adults","author":"FDA News Release","year":"2013"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200767010-00004","article-title":"Serotonergic drugs: effects on appetite expression and use for the treatment of obesity","volume":"67","author":"Halford","year":"2007","journal-title":"Drugs"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0070","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM Study","volume":"20","author":"O\u2019Neil","year":"2012","journal-title":"Obesity"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Behavioral modification and Lorcaserin for overweight and obesity management (BLOOM) study group. Multicenter, placebo-controlled trial of Lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0080","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"for the BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2011","journal-title":"Obesity"},{"issue":"405","key":"10.1097\/MAJ.0b013e31828abcfd_bb0095","first-page":"e1","article-title":"National birth defects prevention study. Use of topiramate in pregnancy and risk of oral clefts","volume":"207","author":"Margulis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1097\/MAJ.0b013e31828abcfd_bb0100","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","article-title":"The FDA\u2019s assessment of two drugs for chronic weight management","volume":"367","author":"Colman","year":"2012","journal-title":"N Engl J Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291530690X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291530690X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T06:38:52Z","timestamp":1531982332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296291530690X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S000296291530690X"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31828abcfd","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}